BI 224436

From Wikipedia, the free encyclopedia
Jump to: navigation, search
BI 224436
BI 224436.svg
Systematic (IUPAC) name
(2S)-[4-(3,4-Dihydro-2H-chromen-6-yl)-3-quinolinyl][(2-methyl-2-propanyl)oxy]acetic acid
Clinical data
Legal status
  • Investigational
Pharmacokinetic data
Biological half-life 7 hrs (simulated)[1]
ATC code None
ChemSpider 27289461
Chemical data
Formula C24H25NO4
Molecular mass 391.460 g/mol

BI 224436 is an investigational new drug under development for the treatment of HIV infection. BI 224436 is the first non-catalytic site integrase inhibitor (NCINI). It inhibits HIV replication via binding to a conserved allosteric pocket of the HIV integrase enzyme. This makes the drug distinct in mechanism of action compared to raltegravir and elvitegravir, which bind at the catalytic site.[2] In October 2011, Gilead Sciences purchased exclusive rights to develop BI 224436 and several related compounds under investigation in Boehringer Ingelheim’s noncatalytic site integrase inhibitor program.[3][4]